Hormonal and renal responses to atrial natriuretic peptide infusion in low-renin hypertension

What Was Tested

Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

Although atrial natriuretic peptide (ANP) levels are often elevated in low-renin hypertensives, the renal and hormonal effects of ANP infusion have never been evaluated in these patients.

The remaining hypertensives (n = 18, age 41 +/- 4 years) were classified into the normal-renin group.

Who Took Part

According to the abstract, 27 men were involved.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The men were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

Blinding on both sides kept the men and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

Each person switched between ANP (Atrial Natriuretic Peptide) and the comparison at some point, usually with a gap in between.

A time span of 1 week appears in the methods.

What Was Measured

Although atrial natriuretic peptide (ANP) levels are often elevated in low-renin hypertensives, the renal and hormonal effects of ANP infusion have never been evaluated in these patients.

Topics PubMed links to this paper include Aldosterone, Atrial Natriuretic Factor, Glomerular Filtration Rate, Hypertension, Kidney, Natriuresis and Renin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of ANP (Atrial Natriuretic Peptide) in 27 men over 1 week.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (American journal of nephrology), a journal based in Switzerland.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.